» Articles » PMID: 15693854

Podoplanin As a Marker for Mesothelioma

Overview
Journal Pathol Int
Specialty Pathology
Date 2005 Feb 8
PMID 15693854
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Podoplanin is a specific marker for lymph vessel endothelial cells. It was noted that podoplanin is expressed in reactive mesothelial cells. The utility of podoplanin for the histological diagnosis of tumors was then investigated, especially for mesothelioma. Immunohistochemical study of podoplanin was carried out in five malignant mesotheliomas and 118 other tumors including 93 adenocarcinomas, four squamous cell carcinomas, six gastrointestinal stromal tumors and five endocrine tumors. Immunoreactivity for podoplanin was demonstrated on the cell membrane of tumor cells for all mesotheliomas. All other tumors were negative for podoplanin. Among the many antibodies used for differential diagnosis of malignant mesothelioma, podoplanin has the potential to be an excellent tumor marker in both specificity and sensitivity. The utility of podoplanin as a marker for mesothelioma will be confirmed by further studies.

Citing Articles

Combining RNAscope, Immunohistochemistry (IHC) and Digital Image Analysis to Assess Podoplanin (PDPN) Protein and PDPN_mRNA Expression on Formalin-Fixed Paraffin-Embedded Normal Human Placenta Tissues.

Tomescu L, Cosma A, Pasca Fenesan M, Melnic E, Petrovici V, Sarb S Curr Issues Mol Biol. 2024; 46(6):5161-5177.

PMID: 38920982 PMC: 11202497. DOI: 10.3390/cimb46060310.


Cancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines.

Tsantes A, Petrou E, Tsante K, Sokou R, Frantzeskaki F, Domouchtsidou A Cancers (Basel). 2024; 16(11).

PMID: 38893201 PMC: 11171168. DOI: 10.3390/cancers16112082.


Prognostic significance of tumor budding in patients with pancreatic invasive ductal carcinoma who received neoadjuvant therapy.

Ibuki E, Kadota K, Kimura N, Ishikawa R, Oshima M, Okano K Heliyon. 2024; 10(1):e23928.

PMID: 38205326 PMC: 10777074. DOI: 10.1016/j.heliyon.2023.e23928.


Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment.

Pavlovic D, Niciforovic D, Markovic M, Papic D Clin Med Insights Oncol. 2023; 17:11795549231220297.

PMID: 38152726 PMC: 10752082. DOI: 10.1177/11795549231220297.


Mechanisms of cancer-associated thrombosis.

Hisada Y, Mackman N Res Pract Thromb Haemost. 2023; 7(3):100123.

PMID: 37122533 PMC: 10139954. DOI: 10.1016/j.rpth.2023.100123.